Gene therapy
Gene therapy is a therapeutic approach that delivers, replaces, regulates, or otherwise modifies genetic information to treat disease.
Gene therapy is a therapeutic approach that delivers, replaces, regulates, or otherwise modifies genetic information to treat disease. Depending on the disease and delivery system, the intended effect may be restoration of a missing protein, correction or compensation for a pathogenic genetic defect, modulation of cellular activity, or introduction of a therapeutic gene. The recent literature represented here includes adeno-associated virus (AAV) and other viral vectors, plasmid DNA, messenger RNA, small interfering RNA, CRISPR-Cas methods, lipid nanoparticles, and biodegradable nanocarriers as relevant genetic-medicine platforms.
Its biomedical significance spans inherited, neurological, hematological, hepatic, ocular, and malignant diseases. Examples include endogenous production of clotting factors in hemophilia, restoration of hepatocyte expression of the bile salt export pump (BSEP) in progressive familial intrahepatic cholestasis type 2, modulation of inhibitory neurons in epilepsy, and targeted treatment strategies for sickle-cell disease, GM2 gangliosidoses, and triple-negative breast cancer. The publications summarized below collectively extend translational applications across rare-disease models, tissue-specific delivery, cancer combinations, therapeutic regulation, and health-economic evaluation.
Where the papers sit
14 papers from the last 6 months study gene therapy directly · updated from PubMed 13 Nov 2026
Study type 0 clinical trials · 3 human data · 10 preclinical · 1 unclassified
Themes 3 themes · 1 paradigm shift
-
Gene Therapy for Rare Disorders
AAV-based correction is being extended across inherited neurologic, hepatic and sensory disorders. CNS studies target inhibitory neurons or use focused ultrasound to improve brain delivery, with seizure suppression and phenotypic rescue as recurring endpoints. Liver-directed treatment improves progressive familial intrahepatic cholestasis in mice, while intravenous therapy prolongs survival in Sandhoff disease. Variant classification and nonviral nanocarriers remain open translational challenges.
8 papers · 57.1%
-
Multimodal Triple-Negative Breast Cancer
Treatment is moving toward multimodal strategies that combine targeted delivery, immune activation and ferroptotic cell death in triple-negative breast cancer. Antibody-drug conjugates are paired with cmLumiOpto, while sonosensitive Fe-TCPP carriers deliver siATAD3A for sonodynamic co-gene-ferroptosis therapy. Gut microbiota modulation and altered tyrosine metabolism are proposed to potentiate PD-1-mediated immunity. These approaches remain preclinical, with apoptosis, tumor control and immune response as recurring endpoints.
3 papers · 21.4%
-
Others — Sickle Cell Treatment Strategies
Curative approaches are being compared with hydroxycarbamide and standard care in sickle-cell disease. Allogeneic stem-cell transplantation and gene therapy are assessed through blood rheology, clinical outcomes and cost-effectiveness. Haploidentical transplantation broadens donor access but must be weighed against gene therapy and established treatment. The cluster also touches biomedical regulation, leaving implementation and long-term comparative value unresolved.
3 papers · 21.4%
Gene therapy can function as a circuit-level treatment for epilepsy rather than only as molecular replacement or disease-directed genetic delivery
The clinical chemogenetic epilepsy study and the AAV-GAD65 seizure-model study both use gene therapy to reconfigure neural activity rather than to replace a defective disease gene: the former makes brain cells pharmacologically suppressible, reducing seizures in three patients, while the latter targets inhibitory interneurons to increase GABA, normalize abnormal activity, and improve seizure-model outcomes 43019411Nov 42349402Jun. Together, findings from a clinical system and experimental models displace the set's predominant view of gene therapy as delivery of a corrective or disease-directed molecular payload. The resulting role is an engineered, potentially controllable neuromodulatory intervention in which the therapeutic effect comes from changing circuit behavior.
Papers
The 14 papers from the last 6 months that study gene therapy directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Gene Therapy for Rare Disorders (8)
- Novel gene therapy lets drug dampen brain cell activity, reducing seizures. Science (New York, N.Y.) · 12 Nov 2026 PMID 43019411
- A translational pipeline for classification of variants of uncertain significance to support gene therapy clinical trial in OTOF-related deafness. Cell reports. Medicine · 7 Oct 2026 PMID 42843343
- Intravenous gene therapy improves life span and clinical outcomes in a feline model of Sandhoff disease. Science translational medicine · 9 Sept 2026 PMID 42715347
- Construction and In Vitro Evaluation of a CS-PLGA/pEGFP/HA Ternary Biodegradable Nanocarrier as a Potential Candidate for Intravitreal Ocular Gene Delivery. ACS applied bio materials · 7 Sept 2026 PMID 42702980
- Focused Ultrasound is Poised to Take Non-Viral Gene Therapies to the Blood-Brain Barrier - and Beyond. Cell biomaterials · 3 Sept 2026 PMID 42688794
- Liver-directed gene therapy results in amelioration of progressive familial intrahepatic cholestasis type 2 in mice. Hepatology communications · 11 Aug 2026 PMID 42579774
- AAV-mediated gene therapy demonstrates phenotypic rescue in a mouse model of Cockayne syndrome. The Journal of clinical investigation · 30 Jul 2026 PMID 42531030
- A compact GAD67 promoter enables inhibitory neuron-targeted AAV gene therapy for seizure suppression. Molecular therapy : the journal of the American Society of Gene Therapy · 25 Jun 2026 PMID 42349402
Multimodal Triple-Negative Breast Cancer (3)
- Folic-Acid-Modified Fe-TCPP Metal-Organic Frameworks as Sonosensitive Agents and siATAD3A Carriers for Sonodynamic Co-Gene-Ferroptosis Therapy in Triple-Negative Breast Cancer. ACS biomaterials science & engineering · 1 Sept 2026 PMID 42679356
- Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment. Cell reports. Medicine · 24 Jul 2026 PMID 42497865
- Lactobacillus rhamnosus modulates gut microbiota and tyrosine metabolism to potentiate PD-1-mediated anti-tumor immunity in triple-negative breast cancer. International immunopharmacology · 20 May 2026 PMID 42161051
Others — Sickle Cell Treatment Strategies (3)
- Blood rheology after allogeneic hematopoietic stem cell transplantation or gene therapy in sickle cell disease. Blood advances · 14 Jul 2026 PMID 42448317
- Closing the gap? China's new regulation on biomedical technologies. Stem cell reports · 25 Jun 2026 PMID 42349422
- Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis. Blood · 2 Jun 2026 PMID 42227898
By study type
Human data, design not indexed (3)
- Novel gene therapy lets drug dampen brain cell activity, reducing seizures. Science (New York, N.Y.) · 12 Nov 2026 PMID 43019411
- Blood rheology after allogeneic hematopoietic stem cell transplantation or gene therapy in sickle cell disease. Blood advances · 14 Jul 2026 PMID 42448317
- Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis. Blood · 2 Jun 2026 PMID 42227898
Preclinical: animal, cell and lab studies (10)
- A translational pipeline for classification of variants of uncertain significance to support gene therapy clinical trial in OTOF-related deafness. Cell reports. Medicine · 7 Oct 2026 PMID 42843343
- Intravenous gene therapy improves life span and clinical outcomes in a feline model of Sandhoff disease. Science translational medicine · 9 Sept 2026 PMID 42715347
- Construction and In Vitro Evaluation of a CS-PLGA/pEGFP/HA Ternary Biodegradable Nanocarrier as a Potential Candidate for Intravitreal Ocular Gene Delivery. ACS applied bio materials · 7 Sept 2026 PMID 42702980
- Folic-Acid-Modified Fe-TCPP Metal-Organic Frameworks as Sonosensitive Agents and siATAD3A Carriers for Sonodynamic Co-Gene-Ferroptosis Therapy in Triple-Negative Breast Cancer. ACS biomaterials science & engineering · 1 Sept 2026 PMID 42679356
- Liver-directed gene therapy results in amelioration of progressive familial intrahepatic cholestasis type 2 in mice. Hepatology communications · 11 Aug 2026 PMID 42579774
- AAV-mediated gene therapy demonstrates phenotypic rescue in a mouse model of Cockayne syndrome. The Journal of clinical investigation · 30 Jul 2026 PMID 42531030
- Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment. Cell reports. Medicine · 24 Jul 2026 PMID 42497865
- Closing the gap? China's new regulation on biomedical technologies. Stem cell reports · 25 Jun 2026 PMID 42349422
- A compact GAD67 promoter enables inhibitory neuron-targeted AAV gene therapy for seizure suppression. Molecular therapy : the journal of the American Society of Gene Therapy · 25 Jun 2026 PMID 42349402
- Lactobacillus rhamnosus modulates gut microbiota and tyrosine metabolism to potentiate PD-1-mediated anti-tumor immunity in triple-negative breast cancer. International immunopharmacology · 20 May 2026 PMID 42161051
Unclassified: not yet indexed with MeSH (1)
- Focused Ultrasound is Poised to Take Non-Viral Gene Therapies to the Blood-Brain Barrier - and Beyond. Cell biomaterials · 3 Sept 2026 PMID 42688794
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-09-11. Drafted by language models from published abstracts; not medical advice.